Drugs being repurposed in hopes they will help against COVID-19 cost relatively little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert has said.
"Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively," said Andrew Hill, a research fellow at the University of Liverpool.
"Otherwise, supplies of these drugs could quickly run out."